| Literature DB >> 23564631 |
Kavishwar Balwant Wagholikar1, Kathy L MacLaughlin, Thomas M Kastner, Petra M Casey, Michael Henry, Robert A Greenes, Hongfang Liu, Rajeev Chaudhry.
Abstract
OBJECTIVES: We previously developed and reported on a prototype clinical decision support system (CDSS) for cervical cancer screening. However, the system is complex as it is based on multiple guidelines and free-text processing. Therefore, the system is susceptible to failures. This report describes a formative evaluation of the system, which is a necessary step to ensure deployment readiness of the system.Entities:
Keywords: Crowdsourcing; Decision Support Systems, Clinical; Guideline Adherence; Uterine Cervical Neoplasms; Vaginal Smears; Validation Studies as Topic
Mesh:
Year: 2013 PMID: 23564631 PMCID: PMC3721177 DOI: 10.1136/amiajnl-2013-001613
Source DB: PubMed Journal: J Am Med Inform Assoc ISSN: 1067-5027 Impact factor: 4.497
Figure 1Architecture of the system. CDSS, clinical decision support system; EHR, electronic health record.
Figure 2Guideline flowchart for the proof of concept system. It represents the guideline rulebase implemented in the clinical decision support system. ASC-US, atypical squamous cells of undertermined significance; G/C, gynecology clinic; HPV, human papilloma virus; PAP, Papanicolaou.
Figure 3Interface of the web-system used by care providers to participate in the study. HPV, human papilloma virus; PAP, Papanicolaou.
Figure 4Study design. CDSS, clinical decision support system.
Figure 5Summary of test set construction and CDSS evaluation results, showing number of cases in each step of the study. CDSS, clinical decision support system; EHR, electronic health record.
Distribution of CDSS errors over different decision scenarios
| Test cases | Patient variables | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Hysterectomy | Age (years) | Recent HPV | Previous HPV | High risk | ETZ adequate | Cytology | Grouped decision scenarios | % Incorrect by CDSS | |
| 12 | Yes | Hysterectomy | 17 | ||||||
| 3 | ≥66 | No | No report | Cytology report absent | 13 | ||||
| 3 | ≥30 & <66 | No report | |||||||
| 8 | ≥21 & <30 | No report | |||||||
| 10 | <21 | No report | |||||||
| 13 | Pos | ASCUS | ASCUS | 4 | |||||
| 11 | Neg | ASCUS | |||||||
| 2 | NP | ASCUS | |||||||
| 1 | Pos | pos | Neg | Cyto negative and HPV pos | 0 | ||||
| 7 | Nos | pos/NP/absent | Neg | ||||||
| 2 | Yes | No | Neg | Cyto and HPV neg and ETZ inadequate | 25 | ||||
| 2 | <21 | No | No | Neg | |||||
| 2 | >65 | No | No | Neg | |||||
| 1 | ≥30 | Neg/NP | No | No | Neg | ||||
| 6 | ≥30 | Neg/NP | No | No | Neg | ||||
| 11 | ≥21 & <30 | Neg/NP | No | No | Neg | ||||
| 15 | ≥30 | Neg/NP | No | Yes | Neg | Cyto and HPV negative | 14 | ||
| 18 | ≥30 & <66 | Neg/NP | No | Yes | Neg | ||||
| 10 | ≥21 & <30 | Neg/NP | Yes | Neg | |||||
| 10 | ≥30 | Neg/NP | Yes | Yes | Neg | Normal cytology high risk | 0 | ||
| 5 | ≥66 | No | Unsatis. | Unsatis. | 33 | ||||
| 1 | ≥66 | Yes | Unsatis. | ||||||
| 5 | ≥30 & <66 | Unsatis. | |||||||
| 1 | ≥21 & <30 | Unsatis. | |||||||
| 10 | Abnormal (other than ASCUS) | Abnormal (other than ASCUS) | 0 | ||||||
| 169 | 13 | ||||||||
The combination of patient variables corresponds to decision scenarios that are grouped for readability and interpretation in the last two columns.
ASCUS, atypical squamous cells of undertermined significance; CDSS, clinical decision support system; Cyto, cytology; ETZ, endocervical transformation zone; HPV, human papillomavirus; NP, not performed; Unsatis, unsatisfactory for evaluation.
Listing and classification of CDSS errors (corresponds to figure 6)
| Grouped decision scenarios | Error description | Error number | Type of error |
|---|---|---|---|
| Hysterectomy | Missed history of hysterectomy in problem list | 6 | Programming |
| Missed a case of hysterectomy when not mentioned in problem list, but found in clinical note. This information is now obtained from patient provided data sources | 10 | Programming | |
| Report absent | If cytology report is absent and age is <21 years, recommendation should be perform Pap-HPV reflex at age 21 years, instead of saying no recommendation | 11 | Modeling |
| When the cytology report is not found, there needs to be an upper age limit for recommending screening ‘now’ for low-risk patients. For high-risk patients screening should be recommended even when age >65 years | 4 | ||
| ASCUS | Missing decision scenario: when cervical cytology is ASCUS and HPV is not performed recommendation should be ‘Cytology at 6 and 12 months’ | 7 | Modeling |
| Cyto and HPV neg ETZ inadequate | When the cytology and HPV are negative but ETZ is inadequate examine age instead of age at recent report to recommend next screening | 5 | Programming |
| When cytology and HPV are negative and in adequate ETZ, recommend Pap-HPV reflex at 6 or 12 months if last test was co-test, or recommend Pap-HPV co-test at 6 or 12 months if last test was reflex | 8 | Modeling | |
| When the cytology and HPV are negative but ETZ is inadequate, there is a need for upper age limit | 9 | Modeling | |
| Excluded consideration of inadequate ETZ for high-risk patients | 12 | Modeling | |
| Normal cytology | For determining high risk exclude CIN1 | 3 | Modeling |
| For recommending screening for high risk patients, the upper age limit cut-off needs to be removed, as they would continue annual screen even if >65 years old. For low-risk patients with normal cytology, the upper age limit cut-off needs to be corrected | 2 | Modeling | |
| Unsatisfactory for evaluation | For low-risk patients, there needs to be an upper age limit for recommending repeat test after 3 months | 1 | Modeling |
ASCUS, atypical squamous cells of undertermined significance; CDSS, clinical decision support system; CIN1, cervical intraepithelial neoplasia 1; HPV, human papilloma virus; PaP, Papanicolaou; ETZ, endocervical transformation zone.
Figure 6Modified guideline flowchart. The number in red circles corresponds to the errors described in the text and table 2. The yellow rectangles circumscribe the elements that were appended or modified to make the corrections. ASC-US, atypical squamous cells of undertermined significance; ETZ, endocervical transformation zone; G/C, gynecology clinic; HPV, human papilloma virus; PAP, Papanicolaou.